000098425 001__ 98425 000098425 005__ 20210128133202.0 000098425 0248_ $$2sideral$$a122187 000098425 037__ $$aART-2019-122187 000098425 041__ $$aeng 000098425 100__ $$0(orcid)0000-0001-5632-0351$$aMarron, S.E. 000098425 245__ $$aPatient reported outcomes (PROS) in psoriasis patients 000098425 260__ $$c2019 000098425 5060_ $$aAccess copy available to the general public$$fUnrestricted 000098425 5203_ $$aP20 Introduction: Psoriasis is a chronic skin disease with negative physical, mental and social manifestations. Method: We carried out a longitudinal and prospective study under routine clinical practice conditions. The objective of the study was to measure quality of life with the Short Form-36 Survey (SF-36) and correlate the results with clinical variables using the PASI and BSA in a group of 17 patients with moderate to severe psoriasis treated with Ustekinumab. Results: In the baseline evaluation we observed the following results: 35.3% reported physical malfunction, 64.7% debilitating pain, 82.3% poor health in general, 76.4% bad vitality, 88.2% social malfunction, 100% emotional malfunction and 82.3% poor mental health. At week 78 we observed the following results: 41.15% reported very good physical functioning, 76.1% no pain, 58.8% good general health, 58.8% very good vitality, 70%, 5% good social functioning, 70.5% good emotional functioning and 52.9% good mental health. Conclusion: We observed that the perception of patients with moderate-severe psoriasis regarding their health at the beginning of treatment with Ustekinumab was poor and that they experienced a significant improvement throughout the successive weeks of treatment. 000098425 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000098425 590__ $$a4.016$$b2019 000098425 591__ $$aDERMATOLOGY$$b7 / 68 = 0.103$$c2019$$dQ1$$eT1 000098425 592__ $$a1.01$$b2019 000098425 593__ $$aMedicine (miscellaneous)$$c2019$$dQ1 000098425 593__ $$aDermatology$$c2019$$dQ1 000098425 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion 000098425 700__ $$aCerro-Muñoz, P.A. 000098425 700__ $$aPalma-Ruiz, A.M. 000098425 700__ $$0(orcid)0000-0002-1870-8846$$aSimal-Gil, E.$$uUniversidad de Zaragoza 000098425 700__ $$0(orcid)0000-0003-0365-4301$$aGarcia-Felipe, R.$$uUniversidad de Zaragoza 000098425 700__ $$0(orcid)0000-0001-5456-4299$$aPorta-Aznarez, N.$$uUniversidad de Zaragoza 000098425 700__ $$aMartin-Marco, R. 000098425 700__ $$aBaldellou-Lasierra, R. 000098425 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte-Calzada, Y.$$uUniversidad de Zaragoza 000098425 700__ $$aAlcalde-Herrero, V.M. 000098425 700__ $$aFuentelsaz del Barrio, M.V. 000098425 700__ $$aGarcia-Latasa de Aranibar, F.J.$$uUniversidad de Zaragoza 000098425 700__ $$0(orcid)0000-0002-1691-3280$$aAlvarez-Salafranca, M.$$uUniversidad de Zaragoza 000098425 700__ $$0(orcid)0000-0003-1917-6906$$aTomas-Aragones, L.$$uUniversidad de Zaragoza 000098425 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac 000098425 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología 000098425 773__ $$g99, 8 (2019), 752$$pActa derm.-venereol.$$tACTA DERMATO-VENEREOLOGICA$$x0001-5555 000098425 85641 $$uhttps://www.medicaljournals.se/acta/download/10.2340/00015555-3228/$$zTexto completo de la revista 000098425 8564_ $$s83992$$uhttps://zaguan.unizar.es/record/98425/files/texto_completo.pdf$$yVersión publicada 000098425 8564_ $$s4253197$$uhttps://zaguan.unizar.es/record/98425/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000098425 909CO $$ooai:zaguan.unizar.es:98425$$particulos$$pdriver 000098425 951__ $$a2021-01-28-12:42:48 000098425 980__ $$aARTICLE